- Home
- ADCT vs VTYX Comparison
ADCT vs VTYX Comparison
Compare ADCT & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- VTYX
- Stock Information
- Founded
- ADCT 2011
- VTYX 2018
- Country
- ADCT Switzerland
- VTYX United States
- Employees
- ADCT N/A
- VTYX N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- ADCT Health Care
- VTYX Health Care
- Exchange
- ADCT Nasdaq
- VTYX Nasdaq
- Market Cap
- ADCT 131.8M
- VTYX 154.9M
- IPO Year
- ADCT 2020
- VTYX 2021
- Fundamental
- Price
- ADCT $1.21
- VTYX $1.07
- Analyst Decision
- ADCT Strong Buy
- VTYX Buy
- Analyst Count
- ADCT 5
- VTYX 4
- Target Price
- ADCT $7.75
- VTYX $11.33
- AVG Volume (30 Days)
- ADCT 373.9K
- VTYX 1.4M
- Earning Date
- ADCT 05-05-2025
- VTYX 05-08-2025
- Dividend Yield
- ADCT N/A
- VTYX N/A
- EPS Growth
- ADCT N/A
- VTYX N/A
- EPS
- ADCT N/A
- VTYX N/A
- Revenue
- ADCT $70,837,000.00
- VTYX N/A
- Revenue This Year
- ADCT $6.82
- VTYX N/A
- Revenue Next Year
- ADCT $18.56
- VTYX N/A
- P/E Ratio
- ADCT N/A
- VTYX N/A
- Revenue Growth
- ADCT 1.84
- VTYX N/A
- 52 Week Low
- ADCT $1.05
- VTYX $0.78
- 52 Week High
- ADCT $5.17
- VTYX $5.66
- Technical
- Relative Strength Index (RSI)
- ADCT 39.36
- VTYX 42.90
- Support Level
- ADCT $1.13
- VTYX $1.02
- Resistance Level
- ADCT $1.25
- VTYX $1.18
- Average True Range (ATR)
- ADCT 0.11
- VTYX 0.11
- MACD
- ADCT 0.00
- VTYX 0.03
- Stochastic Oscillator
- ADCT 39.51
- VTYX 65.98
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.